CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis.

@article{Slaets2010CNStargetedLE,
  title={CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis.},
  author={Helena Slaets and Jerome J A Hendriks and Chris Van den Haute and Frea Coun and Veerle Baekelandt and Piet Stinissen and Niels Hellings},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2010},
  volume={18 4},
  pages={684-91}
}
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) with an inflammatory and a neurodegenerative component. The neuropoietic cytokine leukemia inhibitory factor (LIF) is expressed in MS lesions, but its effect on lesion development is far from understood. LIF is an interesting candidate for MS therapy, as it has neuroprotective properties and may also promote the survival of myelinating oligodendrocytes (OLGs). However, therapeutic administration of LIF is… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…